Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...

In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...

The company said Monday that fosigotifator failed to outperform placebo in slowing the neurodegenerative disease, but is ...

A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, ...

Tenvie Therapeutics has unveiled with $200 million and the goal of transforming the neurological treatment landscape, nabbing ...

Most recently, Denali Therapeutics initiated dosing in a global BEACON Phase 2a trial of BIIB122 (DNL151) for LRRK2-associated Parkinson’s disease. Denali’s market cap stands at $2.93 billion ...

Russellville-based Denali Water Solutions LLC, the primary defendant in a lawsuit in which attorneys ask for class-action status, requests the suit against it and Alma-based SSS of Crawford County ...

Shares of DNLI stock opened at $21.26 on Friday. Denali Therapeutics has a 12-month low of $14.56 and a 12-month high of $33.33. The firm has a fifty day moving average of $24.62 and a 200-day ...

William Blair analyst Sarah Schram initiated coverage of Denali Therapeutics (DNLI) with an Outperform rating. The company is equipped with a “differentiated” large molecule transport vehicle ...

William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for neurodegenerative diseases. The analyst highlights that Denali is developing a ...

Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33. Get Denali Therapeutics alerts: Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its ...